A5071473018- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- Liquid Crystal Research Advancements
- Cancer Treatment and Pharmacology
- Genetic factors in colorectal cancer
- Lung Cancer Research Studies
- Advanced Breast Cancer Therapies
- Cancer-related Molecular Pathways
- RNA modifications and cancer
- HER2/EGFR in Cancer Research
- Hepatocellular Carcinoma Treatment and Prognosis
- Lung Cancer Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- Breast Cancer Treatment Studies
- Head and Neck Cancer Studies
- Microtubule and mitosis dynamics
- Brain Metastases and Treatment
- Luminescence and Fluorescent Materials
- Supramolecular Self-Assembly in Materials
- Cancer Research and Treatments
- Ovarian cancer diagnosis and treatment
- Molecular Biology Techniques and Applications
- Neutropenia and Cancer Infections
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Diagnosis and Treatment
Instituto Oncológico Dr. Rosell
2015-2024
Instituto de Nanociencia y Materiales de Aragón
2021-2024
Universidad de Zaragoza
2019-2024
USP Institut Universitari Dexeus
2012-2024
Hospital Universitario Dexeus
2018-2024
Osakidetza
2006-2008
Hospital de Cruces
2006-2008
Trastuzumab deruxtecan (T-DXd) has shown durable antitumor activity in pretreated patients with HER2-positive advanced breast cancer (ABC), but its efficacy not yet been evaluated active brain metastases (BMs). DEBBRAH aims to assess T-DXd or HER2-low ABC and central nervous system involvement.This ongoing, five-cohort, phase II study (NCT04420598) enrolled stable, untreated, progressing BMs, and/or leptomeningeal carcinomatosis. Here, we report findings from non-progressing BMs after local...
When tumour tissue is unavailable, cell-free DNA (cfDNA)can serve as a surrogate for genetic analyses. Because mutated alleles in cfDNA are usually below 1%, next-generation sequencing (NGS)must be narrowed to target only clinically relevant genes. In this proof-of-concept study, we developed panel use ultra-deep identify such mutations cfDNA.Our ('SiRe') covers 568 six genes (EGFR, KRAS, NRAS, BRAF, cKIT and PDGFRα)involved non-small-cell lung cancer (NSCLC), gastrointestinal stromal...
Many advanced cases of cancer show central nervous system, pleural, or peritoneal involvement. In this study, we prospectively analyzed if cerebrospinal fluid (CSF), pleural effusion (PE), and/or ascites (ASC) can be used to detect driver mutations and guide treatment decisions. We collected 42 CSF, PE, ASC samples from non‐small‐cell lung melanoma patients. Cell‐free DNA (cfDNA) was purified quantified by PNA‐Q‐PCR next‐generation sequencing. All were evaluable; clinically relevant detected...
1101 Background: SG is a Trop-2 directed antibody-drug conjugate approved for pts with advanced, pretreated, triple-negative breast cancer (TNBC) and HR+/HER2- cancer. The most common SG-related adverse events (AEs) are neutropenia diarrhea which can lead to treatment modifications. Granulocyte colony-stimulating factor (G-CSF) loperamide (L) frequently used managing these AEs. PRIMED assessing if primary prophylaxis G-CSF L improve the tolerability of SG. Methods: (NCT05520723) an...
We present a liquid-crystal laser device based on the chiral ferroelectric nematic phase (N F * ).The medium is obtained by mixing material with agent and small proportion of fluorescent dye.Notably, in N very low electric fields perpendicular to helical axis are able reorient molecules, giving rise periodic structure whose director profile not single harmonic but contains contribution various Fourier components.This feature induces appearance several photonic bandgaps spectral ranges depend...
The present review focuses on recent examples of molecular structures that are capable establishing self-assemblies both in bulk and solvents.
Abstract BACKGROUND Triple-negative breast cancer (TNBC) is an aggressive tumor characterized by poor outcomes and new treatment strategies are urgently required. The programmed cell death-ligand 1 (PD-L1) antibody (Ab) atezolizumab (ATZ) combined with first-line (1L) nab-paclitaxel (nab-PTX) approved in multiple countries for the of PD-L1-positive patients (pts) advanced TNBC (aTNBC) based on a significant improvement progression-free survival (PFS) numerically higher clinically meaningful...
9510 Background: Sym015, a mixture of 2 humanized antibodies, triggers MET degradation by unique mechanism with superior specificity compared to tyrosine kinase inhibitors (TKIs). The Sym015-01 phase (P)1a trial met, the primary objective identifying recommended P2 dose (RP2D) as 18 mg/kg on cycle 1 day followed 12 Q2W. P2a was expanded enroll Amp/Ex14 ∆ NSCLC patients (pts) based preliminary efficacy findings. Here we present interim safety (n = 45) and (NSCLC cohort, n 20) results from...
Drugs targeting the spindle assembly checkpoint (SAC), such as inhibitors of Aurora kinase B (AURKB) and dual specific protein TTK, are in different stages clinical development. However, cell response to SAC abrogation is poorly understood there no markers for patient selection.A panel 53 tumor lines origins was used. The effects drugs were analyzed by MTT flow cytometry. Copy number status determined FISH Q-PCR; mRNA expression nCounter RT-Q-PCR Western blotting. CRISPR-Cas9 technology used...
MET inhibitors have shown activity in non-small-cell lung cancer patients (NSCLC) with amplification and exon 14 skipping (METΔex14). However, patient stratification is imperfect, thus, response rates varied widely. Here, we studied alterations 474 advanced NSCLC by nCounter, an RNA-based technique, together next-generation sequencing (NGS), fluorescence situ hybridization (FISH), immunohistochemistry (IHC), reverse transcriptase polymerase chain reaction (RT-PCR), exploring correlation...
Endometrial cancer (EC) is the most common gynecologic malignancy in developed countries. Although patients are diagnosed at early stages, 15-20% will relapse despite local treatment. Presently, there no reliable markers to identify with worse outcomes who may benefit from adjuvant treatments, such as chemotherapy, and liquid biopsies be of use this setting. Peritoneal lavages systematically performed during endometrial surgery but little data available about their potential biopsies. We...
Abstract Background: The antibody-drug conjugate trastuzumab deruxtecan (T-DXd) significantly improved survival outcomes of HER2-low advanced breast cancer (ABC) patients (pts) compared to standard chemotherapy in the DESTINY-Breast04 trial. DEBBRAH is assessing efficacy and safety T-DXd HER2[+] ABC pts with a history brain metastases (BM) and/or leptomeningeal carcinomatosis (LMC); here, we report results HER-low pts. Methods: (NCT04420598) multicenter, open-label, five-cohort,...
This work reports the synthesis and characterization of a new family star-shaped tricarboxamides with C3-symmetry that have flexible amide spacers linking tris(triazolyl)triazine core three trialkoxyphenyl groups. The presence groups allows formation intermolecular hydrogen bonds reinforce π-stacking van der Waals interactions, promoting liquid crystalline behavior, self-assembly in solvents leading to organogels. As determined by polarized optical microscopy, differential scanning...
With the advent of precision oncology, liquid biopsies are quickly gaining acceptance in clinical setting. However, some cases, amount DNA isolated is insufficient for Next-Generation Sequencing (NGS) analysis. The nCounter platform could be an alternative, but it has never been explored detection clinically relevant alterations fluids.Circulating-free (cfDNA) was purified from blood, cerebrospinal fluid, and ascites patients with cancer analyzed 3 D Single Nucleotide Variant (SNV) Solid...
Hybrid linear-dendritic block copolymers (LDBCs) having dendrons with a precise number of peripheral groups that are able to supramolecular bind functional moieties challenging materials as versatile polymeric platforms for the preparation nanocarriers. PEG2k-b-dxDAP LDBCs based on polyethylene glycol (PEG) hydrophilic blocks and derived from bis-MPA 2,6-diacylaminopyridine (DAP) units have been efficiently synthesized by click coupling preformed blocks, was demonstrated spectroscopic...
The synthesis, characterization and liquid crystalline electrochemical properties of novel triarylamines, in which the triphenylamine platform is non-symmetrically modified with a 4-(6-oxyhexyloxy)benzoic acid group, are reported. Compounds show columnar behavior, as confirmed through use polarized optical microscopy, differential scanning calorimetry X-ray diffraction. Electrochemical were measured using cyclic voltammperometry, obtaining low oxidation potentials HOMO values that optimum...
Somatic copy number variations (CNV; i.e., amplifications and deletions) have been implicated in the origin development of multiple cancers some these aberrations are designated targets for therapies. Although FISH is still considered gold standard CNV detection, increasing potentially druggable to be assessed makes a gene-by-gene approach time- tissue-consuming. Here we investigated potential next generation sequencing (NGS) custom panels simultaneously determine CNVs across FFPE solid...
In a significant percentage of advanced non-small cell lung cancer (NSCLC) patients, tumor tissue is unavailable or insufficient for genetic analyses at time to progression. We prospectively analyzed the appearance alterations associated with resistance in liquid biopsies NSCLC patients progressing targeted therapies using NGS platform.A total 24 were included study, 22 tyrosine kinase inhibitors and two other treatments. Liquid samples obtained GeneReadTM QIAact Lung DNA UMI Panel, designed...
e18143 Background: Advanced NSCLC p with EGFR mutations have a median PFS of 14 months (m) and OS 27 m when treated erlotinib. In cell lines, tyrosine kinase inhibitors (TKIs) induce p53 translocation from the cytoplasm to nucleus subsequent upregulation Fas caspase activation leading apoptosis, but this mechanism was defective in p53-null cells. We tested whether TP53 influence outcome erlotinib EGFR-mutated p. Expression levels repressor MDM2 were also examined. Methods: assessed status...
Background: Luminal advanced breast cancer (ABC) patients eventually progress on endocrine therapy. REVERT aimed to explore whether eribulin could restore sensitivity in a randomized, non-comparative phase II trial. Methods: Aromatase inhibitor (AI)-resistant with luminal ABC were randomized 1:1 receive +/− AI. Patients stratified by prior cyclin-dependent kinases 4/6 (CDK4/6i) treatment. The primary endpoint was an investigator-assessed overall response rate (ORR) according RECIST version...
Genetic and drug sensitivity assays on primary cultures are not only of basic but also translational interest could eventually aid oncologists in the selection treatments. However, cancer cells need to be identified differentiated from non-tumor always present cultures. Also, successive passages can change proportions these two subpopulations. In this study, we propose fluorescence situ hybridization (FISH) analysis cell smears determine presence tumor obtained patients carrying...